GlassScriptPhysician profile
Angel Sun Puryear
NPI 1265669881
$30,341.87
in general payments reported to CMS, 2019-2025
39 companies · $7,422 in 2025
The $7,422 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,123 · 2020: $1,995 · 2021: $2,718 · 2022: $3,913 · 2023: $3,822 · 2024: $7,349 · 2025: $7,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $5,130 · Travel and Lodging: $650 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,438.39 |
| Consulting Fee | $5,130.00 |
| Travel and Lodging | $650.00 |
| Education | $374.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $3,788.77 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $3,311.58 | 2023-2025 | Zoryve |
| Abbvie INC. | $3,091.99 | 2019-2025 | |
| Janssen Biotech, INC. | $2,973.63 | 2019-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $2,510.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,986.36 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $1,248.05 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Novartis Pharmaceuticals Corporation | $1,187.13 | 2019-2025 | |
| Pfizer INC. | $1,143.21 | 2019-2025 | |
| Amgen INC. | $1,124.96 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $1,048.00 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $787.13 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Paratek Pharmaceuticals, INC. | $777.01 | 2021-2025 | Nuzyra |
| Sun Pharmaceutical Industries INC. | $663.75 | 2019-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $634.90 | 2022-2025 | Sotyktu |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $597.76 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $594.28 | 2019-2025 | |
| Allergan, INC. | $392.80 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $382.86 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Medimetriks Pharmaceuticals, INC. | $363.79 | 2019-2025 | Clindacin Etz, Neo-Synalar |
| Ucb, INC. | $293.97 | 2019-2025 | Bimzelx, Cimzia |
| Vyne Pharmaceuticals INC. | $283.80 | 2020-2021 | |
| Journey Medical Corporation | $181.37 | 2022 | |
| Organon LLC | $162.29 | 2025 | Vtama |
| Gilead Sciences, INC. | $114.19 | 2019 | |
| Celgene Corporation | $113.03 | 2019 | |
| Almirall LLC | $111.79 | 2019-2022 | |
| Dermira, INC. | $79.47 | 2019-2020 | |
| Encore Dermatology INC. | $77.37 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.45 | 2019 | |
| Epi Health, LLC | $56.93 | 2021-2022 | |
| Hill Dermaceuticals, INC. | $40.99 | 2025 | Tolak |
| Botanix Sb INC | $31.71 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $31.01 | 2021-2023 | Pramosone, Naftin |
| Springworks Therapeutics, INC. | $27.15 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.34 | 2022 | |
| Biofrontera INC. | $15.29 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Verrica Pharmaceuticals INC. | $13.88 | 2024 | Ycanth |
| Nabriva Therapeutics, Plc | $13.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Puryear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.